CDER’s current proposal to withdraw the accelerated acceptance of Makena (HPC) was based on a large randomized trial that failed to confirm the benefit of this drug to newborns or reduce the potential risk of PTB. In making the decision to suggest Makena’s withdrawal, CDER also reviewed success from prior scientific tests of progestins (HPC a